Perang iran vs israel ni harga emas naik lagi kot...
minetech ada harapan ke esok.....

hahaha....

https://dayakdaily.com/sarawak-is-germanys-pick-to-invest-in-energy-transition-says-pm/

what happen

maybe yaman war

tengah kutip

Units 1,547,268,900
Issued Share Capital ($$) Malaysian Ringgit (MYR) 89,129,785.790
Listing Date 10 Jan 2024

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3413147

ada news ke ?

very slow....

serba dont have white knight like scable...

silent wb....
can extend expiry date

serba can resumetrading ?

One day show .....

https://www.nst.com.my/business/2021/10/740452/no-reason-bursa-suspend-serba-dinamik-review-findings-are-unofficial

https://focusmalaysia.my/serba-explores-cashless-parking-system-venture-with-melaka-state-govt/

prem got news from where barakah court case won ?

isnin nie gerak laa....

Hope upward....
fly...fly...

On October 19, 2020, the merger of Biocogency into Rafarma was announced and went unnoticed. Although important metrics to determine share valuations have soared as a result of the merger, the share price has not yet caught up reflecting the new increased valuations simply because nobody knows about it yet. As word is likely to spread soon, the share price could begin climbing to more fair and reasonable market valuations, as compared to more well known peers.

Who is Rafarma Pharmaceuticals?

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells cannabis health-related products and specialty pharmaceuticals. The company, formerly known as Johnston Acquisition Corp. changed its name to Rafarma Pharmaceuticals, Inc. and is based in Sandy, Utah with a manufacturing and distribution facility in Russia.

Meet Biocogency

Biocogency owns PJSC "Krasfarma", the largest Russian chemical and pharmaceutical production company with more than 50 years of experience in the production of drugs that meet all national and international quality standards.
The company helps meet the growing needs of health care for high-quality, effective and safe generic pharmaceuticals as well as development and production of innovative pharmaceutical products. Production systems with a strong emphasis on safety are carried out through a coordinated interaction of their quality control department, commercial department, logistics service, and scientific information department and pharmacovigilance services.

A rich history is not the most important thing in the modern pharmaceutical industry. To keep the quality of products on a permanently high level, a program of production modernization is being realized: investments in the company include new industrial lines, engineering systems and control systems, as well as new pharmaceutical products.
Safe and effective generic medicines of PJSC Kraspharma, which are not inferior in clinical efficacy to the original, but sold at affordable prices, have won the trust of both doctors and patients.

Most of the drugs produced are included in Vital and Essential Drugs List (VED) approved by the government of the Russian Federation and sold through multiple international markets.

What Biocogency Adds to Rafarma

This transformative merger starts by restating Rafarma 2019 sales from $11.4 million to $84 million and delivers impressive growth rates of close to 50%.

The Biocogency group includes Russia-based drug companies Bebig and PJSC Kraspharma and industrial firm Slavich. Bebig is focused on developing therapies and diagnostics for cancer care in the Russian markets, including supplying microsources for the treatment of prostate cancer using low-dose brachytherapy. Kraspharma, Russia’s largest chemical and pharmaceutical production company (and crown jewel of the merger), and Slavich, a manufacturer of products for medical equipment and packaging for medical and pharmaceutical products, are both steeped in corporate history going back half a century or more in Russia.

Biocogency also brings leadership committed to growing value as measured by the fact the deal was structured to be non-dilutive to existing RAFA shareholders. To that point, Ilia Shpurov has assumed the position of Chairman of the Board, bringing decades of entrepreneurial – and biotech – success to RAFA.

What’s in it for RAFA? An Immediate Spike in Revenue and Profits

The merger with Biocogency is a game changer for RAFA operations and the top and bottom lines. Consider that in 2019, RAFA generated revenue of approximately $11.4 million and gross profit of $3.4 million. In the latest quarter, ended July 31, 2020, Rafarma reported revenue of $5.3 million and gross profit of $3.1 million, according to filings with OTC Markets Group.

Those results are going to get an immediate shot of adrenaline

Hope so....rocket...

venture in glove industries news at bursa

inix

Latest news ...jan16 court case...any comment?

Debt to director settle 6 dis........hope have good news tomorrow

Good news today...

new board perhaps bring light....

Hai any news from
Talap Munai Service LLP to jointly develop and finance up to US$20 million in the development of Rakushechnoye oil and gas

ALTHOUGH the takeover offer Nexgram Holdings Bhd made on Ire-Tex Corp Bhd is now off the table, it has not stopped regulators from pursuing their investigations on the former’s past dealings.

yes alice want to hear more story from you.....

http://www.bursamalaysia.com/market/listed-companies/company-announcements/4980105

tpy dispose other source....

http://www.bursamalaysia.com/market/listed-companies/company-announcements/4978969

good news or bad...?

heard tpy dispose all share in nexgram....

hi gimmy translate for us ur info

slow counter need fast one like pdz

Nextnation Communication Berhad (NNCB) acquired a 1.5% interest in PT
Goldchild Integritas Abadi (GIA), a coal mining company for a cash
consideration of IDR43.3bn (RM13.8mn, IDR3.140/RM)

Any comment

huge sell today